CSL Limited
CSL
Rang in aandelen
#363
CSL Limited operates as a global biopharmaceutical company, engaged in the... CSL Limited operates as a global biopharmaceutical company, engaged in the research, development, manufacturing, marketing, and distribution of diverse pharmaceutical and allied products. Its extensive international footprint includes key markets such as Australia, the United States, Germany, the United Kingdom, Switzerland, and China. The company is structured into two principal operating segments: CSL Behring and CSL Seqirus. CSL Behring focuses on plasma-derived therapies, encompassing both plasma products and recombinant treatments. This segment also conducts significant research into both plasma and non-plasma therapeutics and derives revenue from intellectual property licensing and royalties. In contrast, CSL Seqirus is dedicated to the manufacturing and worldwide distribution of non-plasma biotherapeutic products, alongside developing a range of influenza-related solutions. Founded in 1916, CSL Limited maintains its corporate headquarters in Parkville, Australia.
Aandeelprijs
$137.94
Marktkapitalisatie
$66.19B
Verandering (1 dag)
-0.50%
Verandering (1 jaar)
-3.59%
Land
AU
Handel CSL Limited (CSL)
Categorie
Healthcare
P/B-ratio voor CSL Limited (CSL)
P/B-ratio op October 2026 TTM: 4.21
Volgens de meest recente financiële rapporten en aandelenkoers van CSL Limited is de huidige P/B-ratio (TTM) 4.21. Eind 2024 had het bedrijf een P/B-ratio van 5.43.
P/B-ratiohistoriek voor CSL Limited van 2000 tot 2026
P/B-ratio aan het einde van elk jaar
| Jaar | P/B-ratio | Wijzigen |
|---|---|---|
| 2026 (TTM) | 4.21 | 6.80% |
| 2025 | 3.94 | -27.38% |
| 2024 | 5.43 | 44.67% |
| 2023 | 3.75 | -8.59% |
| 2022 | 4.11 | -64.62% |
| 2021 | 11.60 | -41.84% |
| 2020 | 19.95 | 52.81% |
| 2019 | 13.06 | -17.71% |
| 2018 | 15.87 | -20.12% |
| 2017 | 19.87 | 32.34% |
| 2016 | 15.01 | -0.22% |
| 2015 | 15.04 | 47.75% |
| 2014 | 10.18 | 1.25% |
| 2013 | 10.06 | 70.32% |
| 2012 | 5.91 | 28.39% |
| 2011 | 4.60 | -10.55% |
| 2010 | 5.14 | 17.45% |
| 2009 | 4.38 | -40.16% |
| 2008 | 7.31 | -12.44% |
| 2007 | 8.35 | 25.21% |
| 2006 | 6.67 | 58.64% |
| 2005 | 4.21 | 53.56% |
| 2004 | 2.74 | 23.37% |
| 2003 | 2.22 | -67.73% |
| 2002 | 6.88 | -56.70% |
| 2001 | 15.89 | 71.69% |
| 2000 | 9.25 | 0.00% |
P/B-ratio voor vergelijkbare bedrijven of concurrenten
| Bedrijf | P/B-ratio | Verschil in P/B-ratio | Land |
|---|---|---|---|
| 6.251 | 48.55% |
US
|
|
| 13.2547 | 214.99% |
US
|
|
| - | - |
CH
|
|
| 6.1824 | 46.92% |
NL
|
|
| 3.2932 | -21.74% |
BE
|
